MRD Status Linked to Time to Next Treatment in MM
Patients with sustained minimal residual disease negativity had longer time to next treatment, regardless of baseline risk characteristics.
Patients with sustained minimal residual disease negativity had longer time to next treatment, regardless of baseline risk characteristics.
Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
Multiple myeloma patients who develop second primary malignancies after auto-HSCT have worse survival outcomes, a study suggests.
High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
The FDA has accepted for priority review the biologics license application for elranatamab to be used as a treatment for patients with relapsed or refractory multiple myeloma.
Pano/GBM is safe and effective as conditioning before ASCT in patients with high-risk or relapsed/refractory multiple myeloma, a study suggests.
Ide-cel improves outcomes in patients with triple-class-exposed multiple myeloma, when compared with standard care, a phase 3 trial suggests.
The presence of 2 or more cytogenetic risk markers is associated with inferior outcomes after transplant in patients with multiple myeloma.